Proof of concept study of cannabinoid based therapeutics
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Cannabinoid based therapeutics Raphael Pharmaceutical (Primary)
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- 20 Jan 2025 New trial record
- 07 Jan 2025 According to Raphael Pharmaceutical media release, Citruslabs completed this proof-of-concept clinical study in the United States under Institutional Review Board (IRB) approval and in compliance with U.S. Food and Drug Administration (FDA) regulations.
- 07 Jan 2025 Results presented in the Raphael Pharmaceutical Media Release.